NAD+ Injectable Administration: Safety and Regulatory Status

Current Status of NAD+ as Injectable

NAD+ is a coenzyme involved in over 400 enzymatic reactions in the body, playing central roles in energy metabolism, DNA repair, gene expression, and stress responses 1
While NAD+ precursors like nicotinamide mononucleotide (NMN) have been studied for oral supplementation, injectable NAD+ is not found in any current clinical practice guidelines for treatment of any condition 1
There are no FDA-approved injectable NAD+ products for clinical use in the United States 1

Injectable administration of substances bypasses normal protective barriers and introduces significant risks including infection risk from improper sterile technique 2
Potential for adverse reactions including hypersensitivity 3
Unknown pharmacokinetics when administered parenterally 2
No standardized dosing protocols exist for injectable NAD+ administration 1
Injectable administration of unapproved substances falls outside standard medical practice 3

The American College of Nutrition recommends oral intake of niacin (a precursor to NAD+) at specific daily amounts: adult males 16 mg/day, adult females 14 mg/day 1
For patients requiring parenteral nutrition, the established dosing of niacin is 40 mg/day 1

The upper limit for free nicotinic acid is 10 mg/day (based on flushing effects) 1
The upper limit for nicotinamide is approximately 900 mg/day for adults 1

NAD(P)H oxidase activity has been implicated in anthracycline-induced cardiotoxicity, raising concerns about NAD supplementation in certain contexts 4